

1 **Neutralization breadth of SARS CoV-2 viral variants following primary series and**  
2 **booster SARS CoV-2 vaccines in patients with cancer**

3  
4 Vivek Naranbhai<sup>1,2,6</sup>, Kerri J St. Denis<sup>3</sup>, Evan C Lam<sup>3</sup>, Onosereme Ofoman<sup>4</sup>, Wilfredo-  
5 Garcia Beltran<sup>3,4</sup>, Cristhian Berrios<sup>4</sup>, Atul K. Bhan<sup>4</sup>, Justin F. Gainor<sup>1</sup>, Alejandro B.  
6 Balazs<sup>3</sup>, A. John Iafrate<sup>1,4\*</sup> on behalf of the CANVAX team,

7  
8 <sup>1</sup>Massachusetts General Hospital Cancer Center, Department of Medicine,  
9 Massachusetts General Hospital, Boston, MA

10 <sup>2</sup>Dana-Farber Cancer Institute, Boston, MA

11 <sup>3</sup>Ragon Institute of MGH, MIT and Harvard

12 <sup>4</sup>Department of Pathology, Massachusetts General Hospital, Boston, MA

13 <sup>6</sup>Center for the AIDS Programme of Research in South Africa, Durban, South Africa

14  
15 **Corresponding author:** A. John Iafrate, Massachusetts General Hospital Cancer  
16 Center, 55 Fruit Street, Boston, MA, 02114

17 [aifrate@partners.org](mailto:aifrate@partners.org)

18  
19 **Research support:** Lambertus family foundation; Donald Glazer Fund

20 **Running header:** SARS-CoV-2 vaccines in cancer patients

21

22 No previous presentations

23 **Summary (150/150 words)**

24 Patients with cancer are more likely to have impaired immune responses to SARS CoV-  
25 2 vaccines. We studied the breadth of responses against SARS CoV-2 variants  
26 followingly primary vaccination in 178 patients with a variety of tumor types, and after  
27 booster doses in a subset. Neutralization of alpha, beta, gamma and delta SARS-CoV-2  
28 variants was impaired relative to wildtype (Wuhan), regardless of vaccine type.  
29 Regardless of viral variant, mRNA1273 was the most immunogenic, followed by  
30 BNT162b2 and then Ad26.COV2.S. Neutralization of more variants (breadth) was  
31 associated with higher magnitude of wildtype neutralization, and increase with time  
32 since vaccination; increased age associated with lower breadth. Anti-spike binding  
33 antibody concentrations were a good surrogate for breadth (PPV=90% at >1000U/ml).  
34 Booster SARS-CoV-2 vaccines conferred enhanced breadth. These data suggest that  
35 achieving a high antibody titer is desirable to achieve broad neutralization; a single  
36 booster dose with current vaccines increases breadth of responses against variants.

37

38 **Keywords:** SARS-CoV-2, mRNA1273, BNT162b2, Ad26.COV2.S, booster dose,  
39 breadth, neutralization, variants

## 40 **Main text**

### 41 **Introduction**

42 Patients with cancer are at increased risk of severe disease and/or death from SARS  
43 CoV-2 infection (Kuderer et al., 2020) and vaccination against SARS-CoV-2 is a  
44 cornerstone of prevention. The magnitude of SARS-CoV-2 spike or receptor-binding  
45 (RBD) antibodies and neutralization titer against wildtype SARS-CoV-2 are robust  
46 correlates of vaccine-mediated protection (Earle et al., 2021; Khoury et al., 2021) but  
47 are not sufficiently validated for use clinically. In the Cancer, COVID and Vaccination  
48 study (CANVAX) of more than 750 patients with cancer, we observed lower humoral  
49 immune responses than in non-cancer controls (Naranbhai et al., JCO In press),  
50 consistent with findings from other cohorts (Addeo et al., 2021; Bird et al., 2021;  
51 Thakkar et al., 2021). In both non-cancer controls and patients with cancer, the  
52 magnitude of response was strongly associated with prior SARS CoV-2 infection and  
53 vaccine type: mRNA1273 was the most immunogenic followed by BNT162b2. Both  
54 mRNA vaccines were markedly more immunogenic than Ad26.COVS.2.S. Finally, booster  
55 vaccines were able to overcome poor responses in CANVAX and other  
56 studies(Greenberger et al., 2021).

57 Evolution of SARS CoV-2 variants with mutations that confer higher  
58 transmissibility or evasion of immune responses pose an ongoing threat, as exemplified  
59 by the rapid rise of the delta variant to global dominance during 2021. We, and others,  
60 have previously observed marked variation of *in vitro* neutralization of viral variants in  
61 healthy individuals (Tada et al., 2021; Wilfredo Garcia-Beltran et al., 2021). There are  
62 few robust data regarding the degree of protection against each variant following  
63 different vaccines in immunocompromised patients, but the frequency of breakthrough  
64 infection resulting in hospitalization appears to be markedly higher for  
65 immunocompromised patients than in the general population, highlighting the impact of  
66 lower immunogenicity and higher risk of severe disease (Hippisley-Cox et al., 2021).  
67 Based on these and other data, additional ‘booster’ vaccine doses have been  
68 recommended for immunocompromised patients in many developed countries. Whilst  
69 these vaccine increase the magnitude of response(Greenberger et al., 2021), whether

70 homologous (i.e. wildtype strain based) ‘booster’ doses enhance the breadth of  
71 protection against variants is uncertain (Cho et al., 2021).

72 We studied the magnitude and breadth of neutralization of SARS CoV-2 variants  
73 following the primary series, and after booster doses of vaccination in patients with  
74 cancer who received one of the SARS-CoV-2 Federal Drug Administration (FDA)  
75 Emergency Use Authorized (EUA) vaccines in the United States.

76

77

## 78 **Results**

79 The CANVAX study is an ongoing prospective cohort study of SARS CoV-2 vaccines in  
80 patients with cancer. For this report, we selected 178 participants of CANVAX without  
81 prior SARS CoV-2 infection who were sampled  $\geq 14$  days after vaccination stratifying  
82 by vaccine type (58 mRNA1273, 60 BNT162b2 and 60 Ad26.COV2S). The baseline  
83 participant characteristics known to affect immunogenicity are shown according to  
84 vaccine type in Table 1, and recapitulate those of the overall CANVAX study:  
85 Ad26.COV2.S recipients were slightly older but the sex, cancer type, and therapy types  
86 were similar between groups.

87

## 88 **Neutralization of alpha, beta, gamma and delta SARS-CoV-2 variants is impaired** 89 **in vaccine recipients**

90 We assessed *in vitro* neutralization of wildtype SARS -CoV-2 (Wuhan strain) and four  
91 viral variants alpha, beta, delta and gamma using an extensively validated high-  
92 throughput pseudovirus neutralization assay (Garcia-Beltran et al., 2021a). These  
93 variants represent recent waves of the pandemic, and harbor both shared and distinct  
94 mutations (Supplementary Table 1) that are targeted by immune responses induced by  
95 vaccination with current vaccines, which all encode wildtype SARS CoV-2 spike protein.  
96 We quantified the serum pseudovirus neutralization titer (pNT50) associated with 50%  
97 reduction in viral entry into ACE2 expressing 293T-cells.

98 Consistent with the overall CANVAX population and other studies (Naranbhai et  
99 al., 2021; Tada et al., 2021), neutralization of wildtype SARS-CoV-2 was highest for  
100 mRNA1273 recipients, followed by BNT162b2 and lowest amongst Ad26.COV2.S

101 recipients. Adjusting for covariates, neutralization was lower among BNT162b2  
102 recipients than mRNA1273 for alpha, gamma and delta variants (Figure 1 and  
103 Supplementary Table 2).

104 We observed marked and significantly neutralization of alpha, beta, delta and  
105 gamma variants for most vaccine groups (Figure 1). The differences were most striking  
106 for the beta variant, where fewer than half of all evaluated donors (41% of mRNA1273,  
107 30% of BNT162b and 18% of Ad26.COVS recipients) had neutralization measurable  
108 above the assay limit of detection. Few patients with cancer in this study had  
109 measurable neutralization against wildtype SARS-CoV-2 and the four variants tested  
110 following receipt of Ad26.COVS (43% against wildtype, 30% against alpha, 18%  
111 against beta, 12% against gamma and 15% against delta).

112

### 113 **Neutralization breadth is associated with wildtype neutralization titer, time since** 114 **vaccination and is reduced with age**

115 Next, we sought to identify correlates of vaccine breadth. In multivariate regression, the  
116 magnitude of neutralization of wildtype SARS-CoV-2 was the strongest correlate of  
117 breadth (effect estimate 1.4 additional variants neutralized per  $\log_{10}$  increase in  
118 neutralization titer, 95% CI 1.1:1.6, adjusted  $p < 0.001$ ; Table 2). Vaccine type did not  
119 independently associate with breadth of neutralization ( $p > 0.1$  for each vaccine). Older  
120 age was associated with narrower breadth of response (effect estimate per 5 year  
121 increase in age -0.09, 95% CI -0.17:-0.01, adjusted  $p = 0.029$ ) . Breadth of response  
122 tended to increase with time after vaccination, even adjusting for the expected initial  
123 increase and later waning in the magnitude of response (effect estimate per week after  
124 vaccination 0.04, 95% CI 0:0.08, adjusted  $p = 0.061$ ).

125

### 126 **Anti-spike binding antibody concentrations are a surrogate for breadth**

127 We measured total binding antibodies against SARS-CoV-2 spike (combined IgA/M/G)  
128 with a commercial (FDA EUA) assay and specific isotypes (IgA, IgG, IgM and combined  
129 IgA/M/G) of antibodies binding the receptor-binding domain with a validated assay we  
130 previously developed (Garcia-Beltran et al., 2021b; Wilfredo Garcia-Beltran et al., 2021).  
131 Anti-RBD responses were dominated by IgG isotype responses, and responses varied

132 by vaccine as previously reported (Supplementary Figure 1). Wildtype neutralization  
133 was more robustly correlated with anti-RBD concentrations (Pearson  $R=0.63$ , 95% CI  
134  $0.53-0.71$ ,  $p<0.001$ ) than overall anti-spike responses (Pearson  $R=0.53$ , 95% CI  $0.41-$   
135  $0.63$ ,  $p<0.001$ ) but both correlations were modest. A response comprised of more  
136 isotypes was not associated with greater breadth after adjusting for neutralization titer  
137 against wildtype virus as having a more isotype diverse response was associated with  
138 neutralization titer ( $p<0.001$ ), as in other studies (Noval et al., 2021).

139 Anti-spike IgA/M/G total antibodies are easily measured in clinical practice,  
140 whereas neutralization is not. An anti-spike IgA/G/M titer  $>1000$  U/ml on the Roche  
141 Elecsys FDA EUA assay was predictive of neutralization breadth (positive predictive  
142 value for neutralization of  $>2$  variants at a titer  $>20$  90%, negative predictive value 88%,  
143 overall sensitivity 95%, overall specificity 78%; Supplementary Figure 2).

144

#### 145 **Additional ‘booster’ SARS-CoV-2 vaccines confer enhanced variant neutralization** 146 **breadth**

147 Since the magnitude of wildtype response associated with breadth, and booster doses  
148 increase the magnitude of wildtype response, we hypothesized that an additional  
149 homologous vaccine dose (or ‘booster’) elicits enhanced heterologous breadth. The  
150 safety of additional doses in this (Ref CANVAX) and prior studies (Ref RCT) has  
151 reported to be comparable to the primary series. In 13 participants with low baseline  
152 response (Supplementary Table 3), booster doses enhanced neutralization of alpha,  
153 beta, gamma and delta variants (Figure 2). Notwithstanding that these participants had  
154 low pre-booster titers (only 1 had measurable neutralization of any strain), the  
155 magnitude of neutralization of alpha, beta, gamma and delta variants was numerically  
156 higher than the overall cohorts who had received the full vaccine series.

157

#### 158 **Discussion**

159 SARS-CoV-2 vaccination induces lower magnitude response in patients with cancer.  
160 Here we studied the breadth of response against SARS-CoV-2 variants as these  
161 represent the leading threat to vaccinated individuals. As in patients without cancer,  
162 vaccination with SARS-CoV-2 vaccines induces lower neutralization of variants,

163 particularly beta, than wildtype. The vaccine types varied in magnitude of response but  
164 crucially, the magnitude of wildtype neutralization response was the primary correlate of  
165 breadth of neutralization. As predicted and concordant with another small study of four  
166 individuals (Iketani et al., 2021), booster doses even with wildtype vaccines increase  
167 breadth against viral variants.

168         These data have several potential clinical implications. First, to achieve the  
169 greatest neutralizing breadth, the most immunogenic vaccine may be preferred as the  
170 primary series for patients at high risk, where feasible. Second, differences in the  
171 effectiveness of the three FDA EUA vaccines in the USA (Naranbhai et al., 2021; Self,  
172 2021) are likely accounted for by differences in magnitude of immunogenicity as  
173 opposed to differences in breadth per se, as each vaccine encodes largely conserved  
174 wildtype spike sequences. Finally, booster doses with wildtype vaccines would be  
175 expected to increase protection against variants in patients with cancer even as we  
176 await next generation of vaccines. This observation is likely because of boosting of  
177 polyclonal responses capable of binding conserved sites in current and predicted future  
178 variants. The magnitude of increase in variant naturalization appears to be robust, even  
179 when responses to initial vaccination are poor, suggesting a single booster dose may be  
180 adequate for most patients to overcome the apparent reduced priming of responses.  
181 Whether these patients may require additional doses due to waning responses remains  
182 unclear.

183         There are several additional noteworthy observations. Increasing age was  
184 associated with reduced breadth of neutralization (independent of magnitude of  
185 response); concordant with impaired immune functions such as poorer somatic  
186 hypermutation, with age(Troutaud et al., 1999). Interestingly we observed a trend  
187 towards enhanced breadth over time, but this is likely small and likely not at the  
188 magnitude seen in individuals with natural infection who continue to accrue increased  
189 breadth over time potentially because of antigen persistence(Cho et al., 2021).  
190 Interestingly, an anti-spike antibody titer higher than 1000 U/ml on the Roche Elecsys  
191 assay, an assay that is widely available in clinical practice, was a good surrogate for  
192 breadth. This may be a helpful threshold in counselling patients regarding need for



193 boosters, notwithstanding limitations of inferring clinical protection from immunologic  
194 measures.

195 A key limitation of this study is the focus on in vitro immunogenicity.  
196 Effectiveness of vaccines against variants is likely to be more complex involving  
197 differences in viral infectivity, exposure rates, transmissibility and possibly virulence in  
198 combination with largely humoral immune responses and cellular responses. This is  
199 illustrated by the exceptional success of the delta variant in transmission, but its  
200 relatively modest escape of neutralization. The number of individuals evaluated after  
201 booster doses is modest, but these represent the extra tail of the curve of patients who  
202 failed to make adequate responses after initial vaccination.

203 In conclusion, while current wildtype-based SARS CoV-2 vaccines induce lower  
204 magnitude responses in patients with cancer that show impaired neutralization of viral  
205 variants, boosting these responses can safely restore breadth against current viral  
206 variants.

207

## 208 **Acknowledgments**

209 We thank the Lambertus Family Foundation and Donald Glazer for support of the  
210 CANVAX study. We thank Andrea Nixon and the MGH Core laboratory for assistance in  
211 performing assays. We wish to thank Michael Farzan, PhD for providing ACE2-  
212 expressing 293T cells. A.J.I. and this study were supported by the Lambertus Family  
213 Foundation. A.B.B. was supported by the National Institutes for Drug Abuse (NIDA)  
214 Avenir New Innovator Award DP2DA040254, the MGH Transformative Scholars  
215 Program as well as funding from the Charles H. Hood Foundation.

216

## 217 **Author Contributions**

218 Conceptualization, V.N., A.J.I.  
219 Methodology, V.N., J.F.G., A.B.B, A.J.I., W.F.G.B.,  
220 Formal Analysis V.N., K.J.S.D, E.C.L  
221 Investigation V.N. K.J.S.D, E.C.L, O.O., W.F.G.B., C.B., A.B.B.  
222 Data Curation V.N.  
223 Writing-Original Draft V.N.



224 Writing-Review & Editing V.N., K.J.S.D, E.C.L, O.O., W.F.G.B., C.B., A.B., J.F.G.,  
225 A.B.I., A.J.I.

226 Visualization V.N.

227 Supervision J.F.G., A.B.B, A.J.I.

228 Funding acquisition J.F.G., A.B.B, A.J.I.

229

### 230 **Declaration of Interests**

231 JFG has served as a compensated consultant or received honoraria from Bristol-Myers  
232 Squibb, Genentech, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead,  
233 Moderna, AstraZeneca, Pfizer, Novartis, Merck, and GlydeBio; research support from  
234 Novartis, Genentech/Roche, and Ariad/Takeda; institutional research support from  
235 Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck,  
236 Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an  
237 employee with equity at Ironwood Pharmaceuticals. AJI has served as a compensated  
238 consultant for Oncoclinicas Brasil, Kinnate, Repare, and Paige.ai.

239

### 240 **Inclusion and Diversity Statement**

241 We worked to ensure gender balance in the recruitment of human subjects. We worked  
242 to ensure ethnic or other types of diversity in the recruitment of human subjects. One or  
243 more of the authors of this paper self-identifies as an underrepresented ethnic minority  
244 in science. One or more of the authors of this paper self-identifies as a member of the  
245 LGBTQ+ community. While citing references scientifically relevant for this work, we also  
246 actively worked to promote gender balance in our reference list.

## 247 **Figure Legends**

### 248 **Figure 1: Neutralization of SARS CoV-2 variants following vaccination with** 249 **mRNA1273 (n=58), BNT162b2 (n=60) or Ad26.COV2.S (n=60) in patients with** 250 **cancer.**

251 The y-axis shows pseudovirus neutralization titer 50 (pNT50, defined as the titer at  
252 which the serum achieves 50% neutralization of SARS-CoV-2 wildtype pseudovirus  
253 entry into ACE2 expressing 293T cells). Briefly, lentiviral particles encoding both  
254 luciferase and ZsGreen reporter genes were pseudotyped with the SARS-CoV-2 spike  
255 protein from the strain indicated (see Supplementary Table 1 for sequences) and  
256 produced in 293T cells, titered using ZsGreen expression by flow cytometry and used in  
257 an automated neutralization assay with 50–250 infectious units of pseudovirus co-  
258 incubated with three-fold serial dilutions of serum for 1 h. Neutralization was determined  
259 on 293T-ACE2 cells. A horizontal dotted line is shown at a pNT50 titer of 12 which is the  
260 lower limit of detection (LLOD) of this assay. The geometric mean titer, proportion  
261 positive (at a threshold of 1:12). Statistical comparison of neutralization titers against  
262 each strain between recipients of different vaccines is details in Supplementary Table 2  
263 and denoted by \* on the graph where p-value shows are adjusted for covariates  
264 previously shown to be associated with wildtype virus neutralization (REF) namely age,  
265 chemotherapy, immunotherapy, timing after vaccination, cancer type. Comparison of  
266 neutralization titers for recipients of each vaccine type, against different strains is shown  
267 as the fold change in neutralization, and corresponding p-value (based on a dunnet's  
268 test conducted in GraphPad Prism v9.0).

269

### 270 **Figure 2: Effect of booster doses on neutralization of SARS CoV-2 viral variants in** 271 **patients with cancer (n=13).** The color of each dot indicates the initial vaccine series 272 and additional vaccine as indicated in legend. The geometric mean titer (GMT) and 273 proportion above the lower limit of detection (LLOD=12) is shown.

274

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

GMT	191.4	85.4	22.2	94.7	48.1	18.9	22	18.4	13.3	76.3	33.3	15.3	72.1	32.7	14.7
% >LLOD	85	75	43	72	65	30	40.7	30	18	62	47	12	63	53	15

**Comparisons:  
between vaccine**


adjusted p-value\*

<i>Ref</i>	**	***	<i>Ref</i>	**	***	<i>Ref</i>	<i>ns</i>	**	<i>Ref</i>	***	***	<i>Ref</i>	**	***
------------	----	-----	------------	----	-----	------------	-----------	----	------------	-----	-----	------------	----	-----

**between variants**


fold-change  
p-value

<i>Ref</i>	<i>Ref</i>	<i>Ref</i>	2	1.8	1.2	4.6	8.7	1.7	2.5	2.6	1.4	2.7	2.6	1.5
			***	**	<i>ns</i>	***	***	***	***	***	<i>ns</i>	***	***	*



275  
276

277



278

279

280 **Tables**

281

282 **Table 1: Baseline characteristics of participants in this study**

<b>Characteristic</b>	<b>Overall (n=178)</b>	<b>mRNA1273 (n=58)</b>	<b>BNT162b2 (n=60)</b>	<b>Ad26.CoV2 .S (n=60)</b>	<b>p- value</b>
<b>Age (IQR)</b>	68 (61, 72)	66 (61, 71)	64 (57, 71)	69 (67, 73)	0.014
<b>Sex</b>					0.9
Female	109 (61%)	34 (59%)	38 (63%)	37 (62%)	
Male	69 (39%)	24 (41%)	22 (37%)	23 (38%)	
<b>Chemotherapy*</b>	59 (33%)	21 (36%)	19 (32%)	19 (32%)	0.8
<b>Immunotherapy*</b>	29 (16%)	8 (14%)	11 (18%)	10 (17%)	0.8
<b>Time after 1st dose (days (IQR))</b>	68 (55, 93)	67 (62, 86)	74 (51, 111)	65 (42, 86)	0.054
<b>Cancer type</b>					0.13
Solid	141 (79%)	41 (71%)	50 (83%)	50 (83%)	
BMT	23 (13%)	13 (22%)	6 (10%)	4 (6.7%)	
Hematologic	14 (7.9%)	4 (6.9%)	4 (6.7%)	6 (10%)	

283 \*Within 12 months of vaccination

284 **Table 2: Multivariate regression analysis to identify correlates of breadth of**  
 285 **neutralization.**

	Effect estimate *	95% CI	p-value
<b>Neutralization titer against wildtype SARS CoV-2</b>	1.4	1.1, 1.6	<0.001
<b>Age (per 5 year increase)</b>	-0.09	-0.17, - 0.01	0.029
<b>Vaccine type</b>			
mRNA1273		Ref	
BNT162b2	-0.16	-0.57, 0.25	0.4
Ad26.COVS.S	-0.29	-0.77, 0.18	0.2
<b>Chemotherapy</b>	-0.14	-0.50, 0.22	0.4
<b>Immunotherapy</b>	0.16	-0.30, 0.62	0.5
<b>Time after 1st dose (per week)</b>	0.04	0.00, 0.08	0.061
<b>Cancer type</b>			
Solid		Ref	
Bone marrow transplanted	-0.04	-0.55, 0.47	0.9
Hematologic	0.2	-0.42, 0.81	0.5

286 \*Effect estimates shown are per additional variant neutralized at measurable levels  
 287 (above lower limit of detection).

## 288 **STAR Methods**

### 289 **Patients**

290 The CANVAX study enrolled consenting adult patients at the Massachusetts General  
291 Hospital Cancer Center between April 21 through July 21, 2021. Recruitment and  
292 enrolment procedures have been previously described. For this analysis we randomly  
293 selected participants without prior SARS CoV-2 infection (confirmed by anti-  
294 nucleocapsid antibody testing) who had received each of the three FDA EUA vaccines  
295 (by allocating random numbers to each participant and selecting the first 60).  
296 Participants were samples  $\geq 14$  days after their final dose of vaccine. This study was  
297 approved by the Mass General Brigham Human Research Committee (2021P000746).

298

### 299 **Neutralization assays**

300 We used pseudovirus neutralization assay that we have previously described in detail  
301 elsewhere. In brief, pseudovirus neutralization titer 50 (pNT50) was calculated by taking  
302 the inverse of the serum concentration that achieved 50% neutralization of SARS-CoV-  
303 2 pseudotyped lentivirus particles entry into ACE2 expressing 293T cells. We  
304 introduced mutations corresponding to the SARS CoV-2 variants of concern shown in  
305 Supplementary Table 1 by site directed mutagenesis, and confirmed clones by  
306 sequencing.

307

### 308 **Binding antibody assays**

309 We measured antibodies against the spike protein with the Roche Elecsys Anti-SARS-  
310 CoV-2 S assay (Roche Diagnostics, Indianapolis, USA), at the MGH Core Clinical  
311 laboratory, a CLIA lab. Anti-receptor binding domain antibodies were measured with an  
312 enzyme-linked immunosorbent assay (ELISA) that we have previously described.

313

### 314 **Statistical Methods**

315 Analyses were performed in R (v4.05) using the *gtsummary* packages and `lm()`  
316 functions. We modelled  $\log_{10}$  transformed pseudovirus neutralization titers as the  
317 dependent variable. We selected covariates found to associated with neutralization of  
318 wildtype SARS CoV-2 in the overall CANVAX study comprising  $>600$  individuals these



319 were: age, days post-vaccination, vaccine type, cancer type (categorized into solid,  
320 bone-marrow transplant or hematologic), receipt of chemotherapy in prior year and  
321 receipt of immunotherapy in prior year as the independent variables. Figures were  
322 rendered in GraphPad Prism v9.0.  
323

## 324 **References**

- 325
- 326 Addeo, A., Shah, P.K., Bordry, N., Hudson, R.D., Albracht, B., Di Marco, M., Kaklamani,  
327 V., Dietrich, P.-Y., Taylor, B.S., Simand, P.-F., et al. (2021). Immunogenicity of SARS-  
328 CoV-2 messenger RNA vaccines in patients with cancer. *Cancer Cell*.
- 329 Bird, S., Panopoulou, A., Shea, R.L., Tsui, M., Saso, R., Sud, A., West, S., Smith, K.,  
330 Barwood, J., Kaczmarek, E., et al. (2021). Response to first vaccination against SARS-  
331 CoV-2 in patients with multiple myeloma. *Lancet Haematol.* 8, e389–e392.
- 332 Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C.,  
333 Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021). Anti-SARS-CoV-2  
334 receptor binding domain antibody evolution after mRNA vaccination. *Nature*.
- 335 Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber,  
336 G.R., Dull, P., and Plotkin, S.A. (2021). Evidence for antibody as a protective correlate  
337 for COVID-19 vaccines. *Vaccine* 39, 4423–4428.
- 338 Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., Schmidt, A.G., lafrate, A.J., and  
339 Balazs Correspondence, A.B. (2021a). COVID-19-neutralizing antibodies predict  
340 disease severity and survival Graphical abstract Highlights d Severe COVID-19  
341 associates with higher antibody production and neutralization titers d Neutralization  
342 potency of anti-RBD antibodies predicts disease severity and survival d  
343 Immunomodulatory COVID-19-directed therapies modulate antibody responses d  
344 COVID-19 sera neutralize D614 and G614 variants, but not pre-emergent WIV1-CoV.
- 345 Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., Yang, D., Miller, T.E., Feldman, J.,  
346 Hauser, B.M., Caradonna, T.M., Clayton, K.L., Nitido, A.D., et al. (2021b). COVID-19-  
347 neutralizing antibodies predict disease severity and survival. *Cell* 184, 476-488.e11.
- 348 Greenberger, L.M., Saltzman, L.A., Senefeld, J.W., Johnson, P.W., DeGennaro, L.J.,  
349 and Nichols, G.L. (2021). Anti-spike antibody response to SARS-CoV-2 booster  
350 vaccination in patients with B cell-derived hematologic malignancies. *Cancer Cell* 39,  
351 1297–1299.
- 352 Hippisley-Cox, J., Coupland, C.A., Mehta, N., Keogh, R.H., Diaz-Ordaz, K., Khunti, K.,  
353 Lyons, R.A., Kee, F., Sheikh, A., Rahman, S., et al. (2021). Risk prediction of covid-19  
354 related death and hospital admission in adults after covid-19 vaccination: national

355 prospective cohort study. *BMJ* 374, 2244.

356 Iketani, S., Liu, L., Nair, M.S., Mohri, H., Wang, M., Huang, Y., and Ho, D.D. (2021). A  
357 third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and  
358 breadth. *MedRxiv* 2021.08.11.21261670.

359 Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A.,  
360 Subbarao, K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing  
361 antibody levels are highly predictive of immune protection from symptomatic SARS-  
362 CoV-2 infection. *Nat. Med.* 1–7.

363 Kuderer, N.M., Choueiri, T.K., Shah, D.P., Shyr, Y., Rubinstein, S.M., Rivera, D.R.,  
364 Shete, S., Hsu, C.-Y., Desai, A., Lopes, G. de L., et al. (2020). Clinical impact of  
365 COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet* 395, 1907–1918.

366 Naranbhai, V., Garcia-Beltran, W.F., Chang, C.C., Mairena, C.B., Thierauf, J.C.,  
367 Kirkpatrick, G., Onozato, M.L., Cheng, J., Denis, K.J. St., Lam, E.C., et al. (2021).  
368 Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and  
369 Ad26.COVS COVID-19 vaccines. *MedRxiv* 2021.07.18.21260732.

370 Noval, M.G., Kaczmarek, M.E., Koide, A., Rodriguez-Rodriguez, B.A., Louie, P., Tada,  
371 T., Hattori, T., Panchenko, T., Romero, L.A., Teng, K.W., et al. (2021). Antibody isotype  
372 diversity against SARS-CoV-2 is associated with differential serum neutralization  
373 capacities. *Sci. Reports* 2021 111 11, 1–11.

374 Self, W.H. (2021). Comparative Effectiveness of Moderna, Pfizer-BioNTech, and  
375 Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations  
376 Among Adults Without Immunocompromising Conditions — United States, March–  
377 August 2021. *MMWR. Morb. Mortal. Wkly. Rep.* 70, 1337–1343.

378 Tada, T., Zhou, H., Samanovic, M.I., Dcosta, B.M., Cornelius, A., Mulligan, M.J., and  
379 Landau, N.R. (2021). Comparison of Neutralizing Antibody Titers Elicited by mRNA and  
380 Adenoviral Vector Vaccine against SARS-CoV-2 Variants. *BioRxiv* 2021.07.19.452771.


381 Thakkar, A., Gonzalez-Lugo, J.D., Goradia, N., Gali, R., Shapiro, L.C., Pradhan, K.,  
382 Rahman, S., Kim, S.Y., Ko, B., Sica, R.A., et al. (2021). Seroconversion rates following  
383 COVID-19 vaccination among patients with cancer. *Cancer Cell*.

384 Troutaud, D., Drouet, M., Decourt, C., Morvan, C. Le, and Cogné, M. (1999). Age-  
385 related alterations of somatic hypermutation and CDR3 lengths in human V $\kappa$ 4-


386 expressing B lymphocytes. *Immunology* 97, 197.  
387 Wilfredo Garcia-Beltran, A.F., Lam, E.C., St Denis, K., John Iafrate, A., Naranbhai, V.,  
388 and Balazs Correspondence, A.B. (2021). Article Multiple SARS-CoV-2 variants escape  
389 neutralization by vaccine-induced humoral immunity. *Cell* 184, 2372-2383.e9.  
390

## Supplemental Information

Supplementary Figure 1: Concentration of antibodies against SARS-CoV-2 spike protein receptor binding domain (RBD) of a) IgA/M/G total, b) IgA, c) IgG and d) IgM isotypes.



**Supplementary Figure 2:** Association between anti-spike IgA/G/M concentration (Roche Elecsys assay) and neutralization breadth. Variant neutralization was defined as neutralization >20 for each variant. A horizontal line is drawn at an antibody concentration of  $3\log_{10}$  (1000 U/mL), which corresponds to a positive predictive value (PPV) of 90% for >2 variants neutralized.







**Supplementary Table 2: Correlates of neutralization of viral variants in patients with cancer.** Shown are results of multivariate regression model including the covariates shown, with log10 pseudovirus neutralization of each viral variant as the response variable.

Characteristic	Wildtype (Wuhan)			Alpha			Beta			Gamma			Delta		
	Beta	95% CI	p-value	Beta	95% CI	p-value	Beta	95% CI	p-value	Beta	95% CI	p-value	Beta	95% CI	p-value
<b>Age</b>	0.07	-0.12, 0.03	0.002	0.09	-0.13, 0.04	<0.001	0.02	-0.05, 0.00	0.061	0.07	-0.11, 0.02	0.003	0.04	-0.09, 0.00	0.059
<b>Vaccine type</b>															
mRNA1273		Ref			Ref			Ref			Ref			Ref	
BNT162b2	0.38	-0.62, 0.15	0.002	0.33	-0.55, 0.10	0.005	0.08	-0.21, 0.04	0.2	0.39	-0.61, 0.16	<0.001	0.34	-0.57, 0.11	0.003
Ad26.COV2.S	0.89	-1.1, -0.65	<0.001	-0.6	0.37, -0.84	<0.001	0.16	0.03, -0.29	0.013	-0.6	0.37, -0.84	<0.001	0.64	0.40, -0.87	<0.001
<b>Chemotherapy</b>	0.28	-0.49, 0.07	0.008	0.31	-0.51, 0.11	0.002	0.11	-0.22, 0.01	0.04	0.26	-0.45, 0.06	0.012	0.12	-0.32, 0.07	0.2
<b>Immunotherapy</b>	0.08	-0.20, 0.35	0.6	0.02	-0.24, 0.28	0.9	0.06	-0.08, 0.20	0.4	0.04	-0.21, 0.30	0.7	0.04	-0.22, 0.30	0.8
<b>Time after 1st dose (days)</b>	0	-0.03, 0.02	0.7	0.01	-0.01, 0.04	0.2	0.01	0.00, 0.02	0.081	0.01	-0.02, 0.03	0.5	0	-0.03, 0.02	0.8
<b>Cancer type</b>															
Solid		Ref			Ref			Ref			Ref			Ref	
BMT	0.02	-0.28, 0.32	>0.9	0.22	-0.06, 0.51	0.13	0.17	0.02, 0.33	0.031	0.18	-0.11, 0.46	0.2	0.16	-0.13, 0.45	0.3
Heme	0.15	-0.51, 0.21	0.4	0.01	-0.36, 0.33	>0.9	0.02	-0.21, 0.17	0.8	0.03	-0.32, 0.38	0.9	0.11	-0.45, 0.24	0.5

### Supplementary Table 3: Characteristics of patients who received booster vaccine doses

	<b>Cancer type, therapy</b>	<b>Initial Vaccine series</b>	<b>Additional vaccine dose type</b>	<b>Interval between initial and additional dose (days)</b>
1	Cutaneous Squamous Cell Carcinoma on immunotherapy	Ad26.COV2.S	BTN162b2	50
2	Breast cancer previously on chemotherapy	Ad26.COV2.S	BTN162b2	81
3	Breast cancer and marginal zone lymphoma on lenalidomide (no B-cell depleting agent)	Ad26.COV2.S	BTN162b2	81
4	Oral squamous cell cancer receiving targeted therapy and steroids	Ad26.COV2.S	BTN162b2	104
5	Lung cancer on immunotherapy and steroids	Ad26.COV2.S	mRNA1273	86
6	Breast cancer on active chemotherapy	mRNA1273	BTN162b2	96
7	Bone marrow transplanted on immunosuppression	mRNA1273	mRNA1273	79
8	Lung cancer, on chemotherapy and steroids	mRNA1273	mRNA1273	115
9	oral squamous cell cancer receiving chemotherapy, immunotherapy and steroids	BTN162b2	BTN162b2	73
10	lung cancer (early stage) receiving chemoradiation	BTN162b2	BTN162b2	80
11	Breast cancer on targeted therapy	BTN162b2	BTN162b2	108
12	Oral squamous cell cancer receiving chemoradiation	BTN162b2	mRNA1273	78
13	Pancreatic cancer receiving chemotherapy	BTN162b2	mRNA1273	88